Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

uGDB, utilizing next-generation sequencing to detect bladder cancer-associated mutations and DNA alterations, has previously shown associations with recurrence and therapy response.

With the clearance of an investigational new drug application from the FDA, a phase 1/2a study will evaluate VS-7375 in KRAS ...

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for ...

The first patient has been enrolled in a trial evaluating ClarityDX Prostate’s impact on early prostate cancer detection, ...

Douglas A. Tremblay, MD, discusses the data showing disease-modifying potential of ropeginterferon alfa-2b-njft in patients ...

Patients with metastatic colorectal cancer who received frontline immune checkpoint inhibitor therapy had positive OS rates ...

Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum ...

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

Before the emergence of data from the SUNLIGHT trial, there were only 2 options for therapy in advanced colorectal cancer: ...

Arvind Trindade, MD, discusses a large database study looking at rising rates of pancreatic and colon cancer in young adults.